287 related articles for article (PubMed ID: 32648697)
1. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study.
Brunner HI; Quartier P; Alexeeva E; Constantin T; Koné-Paut I; Marzan K; Schneider R; Wulffraat NM; Chasnyk V; Tirosh I; Kallinich T; Kuemmerle-Deschner J; Wouters C; Lauwerys B; Nikishina I; Trachana M; Vougiouka O; Martini A; Lovell DJ; Levy J; Vritzali E; Ruperto N;
Arthritis Rheumatol; 2020 Dec; 72(12):2147-2158. PubMed ID: 32648697
[TBL] [Abstract][Full Text] [Related]
2. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat NM; Horneff G; Kasapcopur O; Schneider R; Anton J; Barash J; Berner R; Corona F; Cuttica R; Fouillet-Desjonqueres M; Fischbach M; Foster HE; Foell D; Radominski SC; Ramanan AV; Trauzeddel R; Unsal E; Levy J; Vritzali E; Martini A; Lovell DJ;
Ann Rheum Dis; 2018 Dec; 77(12):1710-1719. PubMed ID: 30269054
[TBL] [Abstract][Full Text] [Related]
3. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Ruperto N; Quartier P; Wulffraat N; Woo P; Ravelli A; Mouy R; Bader-Meunier B; Vastert SJ; Noseda E; D'Ambrosio D; Lecot J; Chakraborty A; Martini A; Chioato A;
Arthritis Rheum; 2012 Feb; 64(2):557-67. PubMed ID: 21953497
[TBL] [Abstract][Full Text] [Related]
4. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
[TBL] [Abstract][Full Text] [Related]
6. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.
Quartier P; Alexeeva E; Constantin T; Chasnyk V; Wulffraat N; Palmblad K; Wouters C; I Brunner H; Marzan K; Schneider R; Horneff G; Martini A; Anton J; Wei X; Slade A; Ruperto N; Abrams K;
Arthritis Rheumatol; 2021 Feb; 73(2):336-346. PubMed ID: 32783351
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
8. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
[TBL] [Abstract][Full Text] [Related]
9. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis.
Lovell DJ; Giannini EH; Reiff AO; Kimura Y; Li S; Hashkes PJ; Wallace CA; Onel KB; Foell D; Wu R; Biedermann S; Hamilton JD; Radin AR
Arthritis Rheum; 2013 Sep; 65(9):2486-96. PubMed ID: 23754188
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients.
Nishimura K; Hara R; Umebayashi H; Takei S; Iwata N; Imagawa T; Shimizu M; Tomiita M; Seko N; Kitawaki T; Yokota S
Mod Rheumatol; 2021 Jan; 31(1):226-234. PubMed ID: 32552266
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study.
Brunner HI; Tzaribachev N; Vega-Cornejo G; Louw I; Berman A; Calvo Penadés I; Antón J; Ávila-Zapata F; Cuttica R; Horneff G; Foeldvari I; Keltsev V; Kingsbury DJ; Viola DO; Joos R; Lauwerys B; Paz Gastañaga ME; Rama ME; Wouters C; Bohnsack J; Breedt J; Fischbach M; Lutz T; Minden K; Miraval T; Ally MMTM; Rubio-Pérez N; Solau Gervais E; van Zyl R; Li X; Nys M; Wong R; Banerjee S; Lovell DJ; Martini A; Ruperto N;
Arthritis Rheumatol; 2018 Jul; 70(7):1144-1154. PubMed ID: 29481737
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Grönlund MM; Remes-Pakarinen T; Kröger L; Markula-Patjas K; Backström M; Putto-Laurila A; Aalto K; Vähäsalo P
Rheumatology (Oxford); 2020 Apr; 59(4):732-741. PubMed ID: 31359057
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
[TBL] [Abstract][Full Text] [Related]
16. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
Vojinović J; Foeldvari I; Dehoorne J; Panaviene V; Susic G; Horneff G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Akikusa J; Avcin T; Borlenghi C; Arthur E; Tatulych SY; Zang C; Tsekouras V; Vlahos B; Martini A; Ruperto N
Rheumatology (Oxford); 2024 Jan; 63(1):140-148. PubMed ID: 37140539
[TBL] [Abstract][Full Text] [Related]
17. Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study.
Hara R; Umebayashi H; Takei S; Okamoto N; Iwata N; Yamasaki Y; Nakagishi Y; Kizawa T; Kobayashi I; Imagawa T; Kinjo N; Amano N; Takahashi Y; Mori M; Itoh Y; Yokota S
Pediatr Rheumatol Online J; 2019 Apr; 17(1):17. PubMed ID: 31039807
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of canakinumab in the treatment of systemic juvenile idiopathic arthritis in Japanese patients: Results from an open-label Phase III study.
Iwata N; Nishimura K; Hara R; Imagawa T; Shimizu M; Tomiita M; Umebayashi H; Takei S; Seko N; Wakabayashi R; Yokota S
Mod Rheumatol; 2023 Nov; 33(6):1162-1170. PubMed ID: 36399020
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
[TBL] [Abstract][Full Text] [Related]
20. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
